# Anti-PM/Scl Antibody-Positive Dermatomyositis With Rapidly Progressive Interstitial Lung Disease in a 19-Year-Old Male: Clinical Implications of a Presumptive Diagnosis Based on Line Immunoassay Positivity

**Authors:** Nozomi Kawamata, Kei Toumura, Takayuki Kon, Hirofumi Amano

PMC · DOI: 10.7759/cureus.103151 · Cureus · 2026-02-07

## TL;DR

A young man with anti-PM/Scl antibodies developed dermatomyositis and rapidly worsening lung disease, showing how this rare condition can present and be managed when specialized tests are unavailable.

## Contribution

This case illustrates the clinical presentation and management of anti-PM/Scl-positive dermatomyositis with rapidly progressive interstitial lung disease in a young adult.

## Key findings

- Anti-PM/Scl-positive dermatomyositis can present with rapidly progressive interstitial lung disease in young adults.
- Mycophenolate mofetil showed some improvement in lung disease when combined with glucocorticoids.
- Orthogonal testing can confirm anti-PM/Scl positivity when immunoprecipitation is unavailable.

## Abstract

Anti-PM/Scl antibodies are classically linked to systemic sclerosis-polymyositis overlap, but a dermatomyositis phenotype with interstitial lung disease has also been described. However, the clinical course and therapeutic approach for short-term progressive interstitial lung disease in anti-PM/Scl-positive dermatomyositis remain incompletely defined. A 19-year-old Japanese male developed cough and exertional dyspnea after several weeks of progressive myalgia and proximal muscle weakness. Marked creatine kinase elevation, a high-titer nucleolar-pattern antinuclear antibody, Gottron papules, and mechanic’s hands were noted, and dermatomyositis was diagnosed based on muscle magnetic resonance imaging and skin histopathology. High-resolution chest computed tomography showed bilateral, lower-lobe-predominant ground-glass opacities with infiltrative changes, consistent with a subacute-to-rapidly progressive course of interstitial lung disease. Anti-PM/Scl-75 and PM/Scl-100 antibodies were positive by a line immunoassay. As immunoprecipitation was unavailable, orthogonal testing on a different platform (wet protein array) also demonstrated strong positivity, increasing diagnostic confidence. After methylprednisolone pulse therapy, followed by high-dose glucocorticoids, interstitial lung disease findings persisted, prompting initiation and up-titration of mycophenolate mofetil. Imaging abnormalities and serum Krebs von den Lungen-6 improved over time after mycophenolate mofetil initiation, although the independent effect could not be determined because multiple interventions overlapped. Intravenous immunoglobulin was added for residual myositis activity, leading to improvement in muscle enzymes and discharge. This case highlights that anti-PM/Scl-positive dermatomyositis in young adults can present with short-term progressive interstitial lung disease and illustrates a pragmatic diagnostic and therapeutic strategy when immunoprecipitation is not feasible.

## Linked entities

- **Chemicals:** methylprednisolone (PubChem CID 6741), mycophenolate mofetil (PubChem CID 5281078)
- **Diseases:** dermatomyositis (MONDO:0016367), interstitial lung disease (MONDO:0015925), systemic sclerosis (MONDO:0005100), polymyositis (MONDO:0019127)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** SNRNP70 (small nuclear ribonucleoprotein U1 subunit 70) [NCBI Gene 6625] {aka RNPU1Z, RPU1, SNRP70, Snp1, U1-70K, U170K}, RIEG2 (Rieger syndrome 2) [NCBI Gene 6012] {aka ARS, RGS2}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, BTG3 (BTG anti-proliferation factor 3) [NCBI Gene 10950] {aka ANA, ANA/BTG3, APRO4, TOB5, TOB55, TOFA}, TRIM33 (tripartite motif containing 33) [NCBI Gene 51592] {aka DDH4, ECTO, PTC7, RFG7, TF1G, TIF1G}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, EXOSC10 (exosome component 10) [NCBI Gene 5394] {aka PM-Scl, PM/Scl-100, PMSCL, PMSCL2, RRP6, Rrp6p}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, KRT10 (keratin 10) [NCBI Gene 3858] {aka BCIE, BIE, CK10, EHK, EHK2, EHK2A}, IFIH1 (interferon induced with helicase C domain 1) [NCBI Gene 64135] {aka AGS7, Hlcd, IDDM19, IMD95, MDA-5, MDA5}
- **Diseases:** erythema (MESH:D004890), dermal sclerosis (MESH:D016136), OP (MESH:D000092124), myalgia (MESH:D063806), Raynaud phenomenon (MESH:D011928), papules (MESH:D000169), myopathic (MESH:D009135), ILD (MESH:D017563), infertility (MESH:D007246), interstitial abnormalities (MESH:D065167), cough (MESH:D003371), polymyositis (MESH:D017285), arthritis (MESH:D001168), azoospermia (MESH:D053713), dorsal hand lesion (MESH:D000092142), acanthosis (MESH:D000052), DM (MESH:D003882), SSc (MESH:D012595), puffy (MESH:D059369), hemorrhagic (MESH:D006470), pulmonary function impairment (OMIM:608852), respiratory (MESH:D012131), heliotrope rash (MESH:D005076), idiopathic inflammatory myopathies (MESH:D009220), Gottron papule (MESH:C538187), muscle weakness (MESH:D018908), dyspnea (MESH:D004417), hyperkeratosis (MESH:D017488), pulmonary involvement (MESH:C566343), inflammatory (MESH:D007249), Skin sclerosis (MESH:D012871)
- **Chemicals:** PM (MESH:D011399), eosin (MESH:D004801), steroid (MESH:D013256), rituximab (MESH:D000069283), PSL (MESH:D011239), FT3 (-), Hematoxylin (MESH:D006416), Cyclophosphamide (MESH:D003520), Methylprednisolone (MESH:D008775), carbon monoxide (MESH:D002248), MMF (MESH:D009173), oxygen (MESH:D010100)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12969943/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12969943/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12969943/full.md

---
Source: https://tomesphere.com/paper/PMC12969943